AstraZeneca PLC logo

AstraZeneca PLC

AZN
HealthcareNASDAQUnited Kingdom
184.34USD+0.27 (+0.15%)

About AstraZeneca

AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of prescription medicines across various therapy areas.

The company's product portfolio includes:

  • Oncology: Medications like Calquence, Enhertu, Faslodex, Imfinzi, Lynparza, Tagrisso, and Zoladex.

  • Cardiovascular, Renal, and Metabolism: Products such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR

  • Respiratory and Immunology: Treatments including Bevespi/Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris

  • Rare Diseases: Medications like Andexxa/Ondexxya, Soliris, Strensiq, and Ultomiris.

  • Other Areas: The company's marketed products also comprise Synagis for respiratory syncytial virus, Fluenz Tetra/FluMist Quadrivalent for Influenza, Seroquel IR/Seroquel XR for schizophrenia bipolar disease, Nexium, and Losec/Prilosec for gastroenterology, Vaxzevria and Evusheld for covid-19.

AstraZeneca serves healthcare providers through a combination of distributors and local representative offices, covering the United Kingdom, Europe, the Americas, Asia, Africa, and Australasia.

The company collaborates with industry leaders like Regeneron Pharmaceuticals, Neurimmune AG, Ionis Pharmaceuticals, Proteros Biostructures GmbH, and Sierra Oncology, Inc., to expand its research and development capabilities.

Originally known as Zeneca Group PLC, the company changed its name to AstraZeneca PLC in 1999 following a merger.

AstraZeneca was incorporated in 1992 and is headquartered in Cambridge, United Kingdom.

AstraZeneca's Business Strategy

AstraZeneca operates a focused, science-led business model centered on the discovery, development, and commercialization of innovative medicines. The company concentrates on three core therapeutic areas: Oncology, BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology), and Rare Diseases. This strategic focus enables AstraZeneca to…

Available on Finplify

Free account required

Sign up free

Our Take on AstraZeneca

Pros:

High-Quality, Innovation-Driven Portfolio: AstraZeneca has successfully repositioned itself as a science-led biopharmaceutical company, with leadership in oncology, cardiovascular, renal, respiratory, and rare diseases. The company’s focus on biologics and precision medicine has fueled sustained growth.

Deep Pipeline: AstraZeneca has built one of the…

Available on Finplify

Free account required

Sign up free

Company Details

Exchange
NASDAQ
Country
United Kingdom
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Pascal Claude Roland Soriot
Employees
94,300
IPO Date
1993-05-12
ISIN
GB0009895292
Website
astrazeneca.com

Key Metrics

Market Cap
142.89BUSD
P/E Ratio (TTM)
27.55
Net Profit Margin
17.43%
Debt / Asset Ratio
0.26
Dividend Yield (TTM)
1.72%
Volume
177,772
Avg Volume
426,713
Shares Outstanding
3.10B
Free Float
99.57%
β Beta
0.19
52W Range
122.5 - 212.7

Fundamental Analysis

Proprietary 5-category scoring system

Score Fingerprint

Section Scores

Profitability
4.1/5Good
Liquidity
2.6/5Average
Leverage
4.0/5Good
Cash Flow
4.5/5Excellent
Valuation
3.9/5Good

Full Breakdown & Peer Ranking

See the detailed score for every metric and how this stock ranks against its sector peers

Unlock for free
Free to join

Unlock the full research on AstraZeneca

Get the full fundamental score breakdown, business strategy, our investment take, live charts and AI-powered briefings. All in one ad-free workspace.

300+ Curated Stocks

A hand-picked universe of world-class businesses across every major market and sector.

AI Analyst Briefings

Deploy your own AI analyst that monitors your portfolio and delivers daily intelligence reports.

Proprietary Fundamentals

Five-category scoring for every stock — profitability, liquidity, leverage, cash flow, and valuation.